98%
921
2 minutes
20
Purpose: To investigate the efficiency, efficacy, and safety of application new conjunctival forceps combined with high-frequency electrocautery-assisted for treatment of conjunctivochalasis (Cch).
Methods: This study included data from 19 patients (22 eyes)with conjunctivochalasis who underwent treatment from January to December 2023. Cch correction was performed with our new conjunctival forceps (Patent Number: ZL 2022 2 0320601.0), which offers enhanced precision and stability in grasping the conjunctiva, combined with high-frequency electrocautery (Ellman, America) for sutureless correction. Surgical duration was recorded. Cch severity, assessed with lip-parallel conjunctival folds (LIPCOF), along with discomfort scored by Ocular Surface Disease Index (OSDI), were compared pre- and post-operatively. A reduction in LIPCOF grade and complete healing of the conjunctival epithelium post-surgery within one month were considered successful outcomes. Healing and potential complications were checked at one week and one month.
Results: The mean surgical duration was 6.9 ± 1.5 minutes. Significant improvement in LIPCOF grades was observed over time (χ²=62.824, p<0.01), with 59.1% of eyes achieving grade 0 at 1 week postoperatively, increasing to 95.5% at 1 month. OSDI scores showed no difference between preoperative (38.54) and 1-week postoperative (41.67) values (p=0.922), but significantly decreased by 1 month (16.67, p<0.001). Complete healing was noted at electrode contact sites by 1 week, while incisions managed with novel conjunctival forceps showed 75% healing rate; all incisions were fully healed by 1 month. Mild postoperative congestion and edema resolved completely without major complications.
Conclusion: The new conjunctival forceps with high-frequency electrocautery for sutureless Cch correction proved to be efficient, effective, and safe.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289505 | PMC |
http://dx.doi.org/10.3389/fopht.2025.1554316 | DOI Listing |
J Fr Ophtalmol
August 2025
Clinique Ramsay, La Croix du Sud, 52, bis chemin de Ribaute, BAL 505, 31130 Quint-Fonsegrives, France. Electronic address:
Two newly described clinical-anatomical entities form the basis of a common pathogenetic theory for tarsal ectropion and involutional entropion: an isolated dehiscence of the posterior bundle of the lower lid retractors for tarsal ectropion and this plus dehiscence of the anterior bundle for involutional entropion. Based on this unifying algorithm, we propose identical surgical management of these two forms of lid malposition; the surgical goal in both cases is to correct the altered position of the retractors as a priority. Moreover, the local anesthetic, surgical instruments and sutures are the same, as is the conjunctival approach.
View Article and Find Full Text PDFFront Ophthalmol (Lausanne)
July 2025
Foshan Aier Zhuoyue Eye Hospital, Foshan, Guangdong, China.
Purpose: To investigate the efficiency, efficacy, and safety of application new conjunctival forceps combined with high-frequency electrocautery-assisted for treatment of conjunctivochalasis (Cch).
Methods: This study included data from 19 patients (22 eyes)with conjunctivochalasis who underwent treatment from January to December 2023. Cch correction was performed with our new conjunctival forceps (Patent Number: ZL 2022 2 0320601.
Case Rep Ophthalmol
June 2025
Dr D Y Patil Medical College Hospital and Research Centre, Pimpri, India.
Introduction: Inert intraocular foreign body (IOFB) removal depends on the location, type of injury, composition, and size of IOFB and possible serious complications of intraocular surgery. Early management is crucial for better prognosis.
Case Presentation: A 28-year-old male presented to the outpatient department after an alleged workplace accident.
Orbit
June 2025
Oculoplastic and Orbital Surgery, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
Purpose: Müller's muscle-conjunctival resection (MMCR) is a well-established posterior approach to correct mild to moderate ptosis. Traditional methods involve resection of a measured segment of Müller's muscle and conjunctiva, followed by the approximation of resected edges with sutures. In recent years, various sutureless MMCR techniques have been reported.
View Article and Find Full Text PDFClin Ophthalmol
January 2025
John Moran Eye Center, University of Utah, Salt Lake City, UT, USA.
The XEN®45 Glaucoma Treatment System (gel stent; Allergan, an AbbVie company, Irvine, CA, USA) is a minimally invasive bleb-forming surgical device that was originally approved to lower intraocular pressure by diverting the aqueous humor from the anterior chamber to the subconjunctival space (like trabeculectomy) following ab-interno placement. Since approval of the gel stent in multiple countries, the implantation technique has evolved considerably, being performed ab interno or ab externo with open or closed conjunctiva, based on patients' needs and/or surgeons' preferences. Additional technical variations that can facilitate gel stent placement and/or improve outcomes have also emerged.
View Article and Find Full Text PDF